piggyBac transposable element derived 3Genealiases: []
Q-omics provides the consensus-scored PGBD3 profile across patient tissues and cancer cell-line models. PGBD3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PGBD3 is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, PGBD3 RNA expression shows 12,686 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KICH, and UVM as cancer lineages where PGBD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PGBD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PGBD3 survival associations across molecular data types. PGBD3 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PGBD3 RNA expression–survival associations across cancer types. High PGBD3 expression shows unfavorable associations in HNSC, ACC and OV, but favorable associations in LGG, KIRP and PRAD. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for PGBD3 RNA expression.
This table summarizes PGBD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for PGBD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PGBD3 shows lower tumor expression in KICH, KIRC, ESCA and BRCA and higher tumor expression in STAD and CHOL. The KICH box plot shows higher PGBD3 RNA expression in normal versus tumor tissue (log2 FC = −0.100, t-test p = .001).
This table shows molecular features associated with PGBD3 in patient tissues and cancer cell lines. In patient samples, PGBD3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PGBD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in STOMACH.
